Geopolitical and macroeconomic uncertainties
Management cited external environment risks including shipping disruptions and US inflationary pressures, leading to conservative guidance.
SENORESPHARMACEUTICALS / bear-case history
Track the concerns that keep returning.
Senores Pharmaceuticals · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
medium
Working capital days increase
Working capital days rose to 187 days in FY26 from 114 days in FY25, partly due to inventory buildup for new launches. Management expects normalization.
Unbilled revenue buildup
Other financial assets (unbilled revenue) increased to 172 crores from 116 crores, reflecting profit share recognition before cash realization. Management expects plateauing.
Execution risk on ANDA commercialization
30 approved ANDAs are yet to be launched; delays in commercialization could impact revenue visibility.